Skip to main content
. Author manuscript; available in PMC: 2016 Sep 22.
Published in final edited form as: J Leuk (Los Angel). 2015 Apr 21;3(2):178. doi: 10.4172/2329-6917.1000178

Figure 3. Lenalidomide treatment does not affect expression of intracellular XBP1 proteins and surface antigens on breast, colon and pancreatic cancer cells.

Figure 3

The effect of lenalidomide (5 μm, 4 days) was evaluated on the antigen expression of various cancer cells; breast cancer (MDA-MB231, MCF7), colon cancer (LS180, SW480), pancreatic cancer (PATU8902, Panc1). No major changes were detected in the expression levels of (A) intracellular XBP1 unspliced and XBP1 spliced proteins, (B) surface HLA-A2, CD80, CD86 and ICOS ligand, nor (C) surface PD-L1 and PD-L2. Results were obtained by flow cytometry analyses and shown as the MFI (mean fluorescence intensity; n=3, mean ± SE. Groups were compared using an unpaired Student’s t-test and no differences (p > 0.05) were seen in MFI between control and lenalidomide treated tumor cells.